Fast-track status completed for AbbVie and BI’s psoriasis treatment Risankizumab

NICE published a final recommendation for AbbVie and Boehringer Ingelheim’s Risankizumab today, completing fast-track process that sees the psoriasis treatment gain market access in record time. The drug is one of the first treatments to go through NICE’s fast-track appraisal system, which accelerates the review process, whilst also cutting the standard 90-day implementation period down

Continue Reading

European Commission approval for AbbVie’s psoriasis treatment

AbbVie has announced that the European Commission (EC) has approved its interleukin-23 (IL-23) inhibitor Risankizumab, for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. The EC gave approval following results from four Phase III studies, ultIMMa-1, ultIMMa-2, IMMvent and IMMhance which assessed more than 2,000 patients

Continue Reading

NICE recommends Allergan’s Ozurdex and AbbVie’s Humira for Uveitis to prevent vision loss.

National Institute for Health and Care Excellence in England and Wales are backing routine use of Allergan’s Ozurdex and AbbVie’s Humira as treatment for non-infectious posterior uveitis, which is a form of preventable vision loss. The cost regulators published their Final Appraisal Determination recommending the drugs as cost and clinically-effective treatment options for those with

Continue Reading

Biogen & Abbvie’s Zinbryta treatment for MS granted marketing authorisation by EC

Biogen and AbbVie have announced that the European Commission has given marketing authorisation for Zinbryta, to be used as treatment of adult patients with relapsing forms of multiple sclerosis. “With the approval of Zinbryta in the European Union, we are providing a much needed treatment option for people living with MS,” added Michael Severino, M.D.,

Continue Reading